English

svenska
norsk språk
한국어
日本語
Italiano
Deutsch
Español
Pусский
Français
简体中文
You are here: Home » News

News and Events

  • Diabetes is a group of metabolic diseases characterized by hyperglycemia. Hyperglycaemia, in turn, is caused by a defect in insulin secretion or impairment of its biological activity, or both. The prolonged presence of hyperglycemia leads to chronic damage and dysfunction of various tissues, especia
  • The rapid development of my country's Semaglutide intermediates industry began in 2000. At present, there are about 2,000 kinds of raw materials and intermediates needed for the chemical industry every year, and the demand is more than 2.5 million tons. Up to now, the chemical raw materials and inte
  • Diabetes is an increasingly serious global epidemic. As of 2015, 400 million adults worldwide are affected by diabetes, of which about 100 million are in China. Patients with type 2 diabetes are resistant to insulin or cannot secrete enough insulin to maintain normal blood sugar levels. Sustained hi
  • In the Semaglutide intermediates industry, in addition to directly cooperating with downstream customers to carry out contract customized production business, the most important business model is "R&D before sales". The characteristics of competition in the industry can be summarized as access quali
About Us
Chengdu Pukang has a professional R&D team with rich experience, and innovative ideas, which can meet the various needs of customers from custom synthesis to mass production.
Quick Links
Contact Us
​​​​​​​​​​​​​​ No.288 of North Rongtai Avenue,WenJiang district 611137,Chengdu Sichuan
Province,China.
+86-28-63976226
Copyright © 2021 chengdu Pukang Biological Technology Co., Ltd.  Support By Leadong  Sitemap /  Private Policy